|
CHARACTERISTICS
|
ALL PATIENTS
|
BB-CAM
|
p
1
|
|---|
| | |
User
|
Non-user
|
|---|
|
Total Count
|
% of all patients
|
Count
|
% of Total
|
Count
|
% of Total
|
|---|
|
448
|
100%
|
332
|
74.1%
|
116
|
25.9%
|
|---|
|
Therapy line
|
0.053
|
|
Breast-Ca
|
Neoadjuvant
|
70
|
15.6%
|
58
|
82.9%
|
12
|
17.1%
| |
|
Adjuvant
|
89
|
19.9%
|
64
|
71.9%
|
25
|
28.1%
| |
|
Metastasis 1st -line
|
78
|
17.4%
|
45
|
57.7%
|
33
|
42.3%
| |
|
Metastasis 2nd -line
|
50
|
11.2%
|
37
|
74.0%
|
13
|
26.0%
| |
|
Metastasis 3rd -line
|
20
|
4.5%
|
17
|
85.0%
|
3
|
15.0%
| |
|
Metastasis ≥4th -line
|
53
|
11.8%
|
42
|
79.2%
|
11
|
20.8%
| |
|
Recurrence 1st -line
|
8
|
1.8%
|
6
|
75.0%
|
2
|
25.0%
| |
|
Recurrence ≥ 2nd -line
|
5
|
1.1%
|
3
|
60.0%
|
2
|
40.0%
| |
|
Ovarian-Ca
|
Neoadjuvant
|
1
|
0.2%
|
1
|
100.0%
|
0
|
0.0%
| |
|
Adjuvant
|
37
|
8.3%
|
29
|
78.4%
|
8
|
21.6%
| |
|
Recurrent
|
37
|
8.3%
|
30
|
81.1%
|
7
|
18.9%
| |
|
Therapy
|
|
Immune modulation
| |
2
|
0.4%
|
2
|
100.0%
|
0
|
0.0%
|
0.402
|
|
Chemotherapy
| |
278
|
62.1%
|
220
|
79.1%
|
58
|
20.9%
|
0.002
|
|
Antibodies
| |
196
|
43.8%
|
143
|
73.0%
|
53
|
27.0%
|
0.625
|
|
Endocrine
| |
150
|
33.5%
|
100
|
66.7%
|
50
|
33.3%
|
0.011
|
|
Bisphosphonates
| |
129
|
28.8%
|
87
|
67.4%
|
42
|
32.6%
|
0.041
|
- 1p values are not adjusted for multiplicity and have to be interpreted to be exploratory
